CEACAM-8

CEACAM-8

CEACAM-8 Overview

Molecule Name
Non specific cross-reacting antigen 95
Synonyms
CEACAM8,CD66b,CD67,CGM6,NCA-95
Drug Development Progress
Drugs in Clinical Trials1
Approved Drugs1
Highest Development StageApproved
Target Synonym
Non-specific cross-reacting antigen NCA-95,CGM6,Carcinoembryonic Antigen Gene Family Member 6,CD66b Antigen,NCA-95,CD67,Carcinoembryonic antigen CGM6,CD66b,CEACAM8,Carcinoembryonic Antigen Related Cell Adhesion Molecule 8,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8,CD67 Antigen,CEA Cell Adhesion Molecule 8
Background
Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) is also known as CD66b (Cluster of Differentiation 66b), CD66b, CD67, CGM6, NCA-95, and is one of seven human CEACAM family members within the immunoglobulin superfamily. CEACAM family members are a set of widely expressed proteins involved in several biological functions, including cell adhesion, migration, signal transduction, and the regulation of gene expression. Abnormal overexpression and downregulation of some CEACAMs have been described in tumor cells. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM8 is a single chain, two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. It is an activation marker for human granulocytes.

CEACAM-8 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
90Y-DTPA-besilesomabTLX-66Phase 2 ClinicalTelix Pharmaceuticals Ltd
Multiple Myeloma; Neoplasms, Plasma Cell; Plasmacytoma
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Besilesomab99Tcm-BW250-183; TLX-66-CDx; TLX66-CDx; BW-250-183ApprovedCis Bio International SaScintimunEUOsteomyelitisCis Bio International Sa2010-01-11
Osteomyelitis
Details